Capricor Therapeutics, Inc. (CAPR) Q1 FY26 Earnings Call

BLA remains under FDA review with an August 22, 2026 PDUFA target, while commercialization depends on litigation [21][57].

Q1 FY26 results, source: company transcript and SEC filings
QuarterQ1 FY26
Call date2026-05-12
Length52 minutes
EPS$-0.59
EPS consensus$-0.55
Revenue$2.3M
Revenue consensus$40.0M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All CAPR earnings ยท Back to CAPR overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.